UNITED-FIRST-PARTNERS
United First Partners ("UFP"), a leading Special Situations Investment & Advisory Group is pleased to announce it has entered into a strategic alliance with the Mariana Group (“Mariana”), a leading Derivatives and Structured Products brokerage group, which is fully FCA regulated and based in London. The combination of UFP and Mariana creates a mid-sized financial services group with a strong reputation in the Equities and Derivatives space. Consequently, Mariana’s regulated entity has been renamed Mariana UFP LLP (FRN 551170) and oversee in excess of 70 professionals in London covering a broad spectrum of value added financial products and services.
This strategic alliance will add to UFP’s current offering in Equities in Europe, as Mariana is a primarily Derivatives and Structured Products brokerage operation, with a strong reputation amongst its peers. UFP and Mariana anticipate significant synergies across business lines in relation to the regulatory challenges expected in the years to come.
UFP and Mariana have upgraded their facilities and entered into new clearing arrangements in order to give Mariana UFP the tools to compete at the highest level.
In the US, UFP LLC (SEC regulated and member of FINRA and SIPC) will continue to operate as a standalone entity, although UFP and Mariana have plans to significantly expand the existing scope of activities in the region, in particular in the Derivatives segment.
Michael Hadjedj, Co-founder of UFP commented: “We are very excited by the strategic alliance we have formed with Mariana. We believe that our industry needs consolidation and Mariana UFP wants to be at the heart of it. UFP’s strong niche research offering combined with Mariana’s cross-asset execution platform and large market share in the derivatives space is a powerful combination to seize opportunities in our industry.”
Daniel Hawkins, Co-founder and CEO of Mariana added, “We are very pleased to join forces with UFP, which brings to Mariana access to a strong research franchise to complement our existing Macro-Economic and Derivative Strategy offering. We are now working towards generating synergies across the group’s business lines, and leveraging on UFP’s presence in the US. We are also preparing actively for the transition to MIFID II in Europe and feel our enlarged group is well positioned.”
About United First Partners
United First Partners (“UFP”) is a global leading Special Situations Investment & Advisory Group, offering a wide range of merchant banking and investment advisory services to institutional and private clients. These services range from sale and purchase of strategic assets to corporate finance, debt and equity capital markets and wealth management.
Our strategy and core values allowed us to build an extensive customer base including leading hedge funds, private equity funds, long-only funds, corporates, sovereign wealth funds and family offices. Our achievements, independence, unique business model and strong reputation have enabled UFP to become an attractive and reliable partner for business associates and talented professionals.
Over the past 6 years, UFP has been recognised as the #1 independent Pan European Special Situations research by industry leading survey Extel.
For further details, please visit www.utdfirst.com
About Mariana Capital
Mariana Capital Markets is a diversified, independent financial services intermediary providing bespoke advisory and strategy services. The firm was founded in 2009 to create and distribute innovative, high performance investment solutions and provide the highest quality service to our clients.
From our headquarters in the City of London, we offer global financial solutions ranging from Market Strategy and Tax Advisory to Structured Products and Estate Planning Solutions.
These services complement our status as a market leading execution venue for Cash Equities, Equity Futures and Options, Commodities, and Fixed Income products.
For further details, please visit www.marianainvestments.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170509006106/en/
Contact:
Press Enquiries:
Sara Caniggia
+44 207 050 6803
media@utdfirst.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom